ROME, Italy—In what researchers say is the first study evaluating cardiac magnetic resonance (CMR) findings in early rheumatoid arthritis (ERA) patients, cardiovascular abnormalities were significantly worse in patients with ERA than in matched, healthy controls. The study results were presented at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Cardiovascular Concerns…
Search results for: Biologics
Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars
Comparing tacrolimus, mycophenolate mofetil and cyclophosphamide, tacrolimus was the most efficacious. Also, biosimilars may soon be easier to differentiate…
Arthritis May Be Worse in Poor Countries, but Seem Worse in Rich Ones
(Reuters Health)—A study of people with rheumatoid arthritis (RA) finds that those in wealthy nations are more troubled by it, even though people in poor countries have more severe symptoms. The results, tallied from 17 countries, suggest that cultural factors may influence patients’ perception of their illness, and possibly even the results of clinical trials…
Use Behavioral ‘Nudging’ to Tackle Gender, Health Challenges
LONDON (Thomson Reuters Foundation)—Many of the world’s biggest challenges, such as encouraging people to buy life-saving drugs or unpicking deeply rooted sexism, can be tackled by using subtle psychological cues to change the way people behave, according to experts in London. Behavioral economics, also known as “nudging,” is about making people more likely to make…
Novartis Launches First U.S. Biosimilar Drug at 15% Discount
LONDON/ZURICH (Reuters)—Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first biosimilar copy of a biotechnology drug approved in the U.S., at a discount of 15% to the original. The Swiss drugmaker’s generics unit Sandoz said Zarxio, its form of Amgen’s white blood cell-boosting product Neupogen (filgrastim), would…
FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs
(Reuters)—A class of diabetes drugs that include Merck & Co Inc.’s Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006,…
Early, Aggressive Therapy for RA May Result in Cost Savings Long Term
By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…
FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
WASHINGTON (Reuters)—The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts. The FDA said its draft guidance is designed to prevent the inadvertent substitution of non-interchangeable products and to make it easier to monitor and track usage once…
Ustekinumab Found to Be Effective in Adolescents with Psoriasis
NEW YORK (Reuters Health)—Adolescents with moderate to severe psoriasis may respond to the human monoclonal antibody ustekinumab as well as adults, with no unexpected side effects, a new study found. The findings are exciting in part because patients in this age group have limited treatment options, the study’s lead author Dr. Ian Landells, of Memorial…
Epratuzumab Results Disappointing, but Adalimumab Promising
Two Phase 3 trials have shown that epratuzumab did not meet its primary endpoints for treating SLE. Meanwhile, a Phase 3 study has shown adalimumab is effective for treating enthesitis-related arthritis in juveniles…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 70
- Next Page »